Objective: In 2016, there were an estimated 56 870 new cases of thyroid cancer (TC) in the USA. Fine needle aspiration cytology (FNAC) is the most safe, accurate and cost-effective method for the initial investigation of thyroid nodules. FNAC is limited by the inability to diagnose malignancy in follicular-patterned lesions accurately and, as a result, 20%-30% of cases under investigation for TC are classified as cytologically indeterminate, illustrating a problem with current FNAC procedure.
undifferentiated or anaplastic carcinoma (UTC or ATC, respectively).
PTC and FTC emanate from thyroid follicular epithelial cells and are commonly referred to as well-differentiated thyroid carcinomas (DTC). 5, 6 MTCs are derived from neuroendocrine cells and represent approximately 5%-10% of TC. 7 The most common manifestation of TC is as a thyroid nodule.
Thyroid nodules are common in the general population, with a prevalence of 2%-7% when detected by palpation and 50% when searched for using US examination. 5, 8 Despite thyroid nodules having a high incidence rate, approximately 60%-80% are classified as benign, with only 3.5%-10% presenting as malignancies. Fine needle aspiration cytology (FNAC) is the most accurate and cost-effective method for the initial management of thyroid nodules, and its accuracy is higher when it is conducted under US guidance. FNAC is limited by the inability to accurately diagnose malignancy in follicularpatterned lesions, and as a result, more than 20% of cases under investigation for TC are classified as cytologically indeterminate.
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The indeterminate category often requires surgical resection to exclude malignancy definitively; however, since approximately 70% of these lesions are finally shown to be benign, surgery is an unnecessary procedure for the vast majority of cases. 13, 14 In an attempt to overcome limitations of cytology in the detection of cancer, optical spectroscopic techniques have been investigated as adjunct or alternative approaches. 15 Optical spectroscopic methods use the interaction of light with matter to provide a detailed description of the molecular composition of biological tissue, and so these techniques can be used to detect biochemical profiles associated with health or disease.
Raman spectroscopy is a form of vibrational spectroscopy based on inelastic scattering. Raman spectra are obtained by irradiating a sample with monochromatic laser light, which interacts with molecules within the sample and induces molecular vibrations. The change in energy between the incident and inelastically scattered light is called the Raman shift. The Raman spectrum is a plot of the intensity of the scattered light vs the change in energy, given in wavenumbers, cm −1 . [16] [17] [18] The spectrum produced by the probed molecular vibrations represents a detailed biochemical fingerprint of the cellular components.
Raman spectroscopy has shown promising results for the detection of multiple cancers including cervical, gastrointestinal, breast, brain and lung cancer. [19] [20] [21] [22] The application of Raman spectroscopy for TC diagnosis has also been investigated in studies utilising cell lines, [23] [24] [25] and tissue sections. [26] [27] [28] [29] [30] [31] [32] Harris et al 23 applied Raman spectroscopy to two thyroid cell lines, one cancer cell line (8505C, representing UTC) and one benign cell line (Nthy-ori 3-1), to analyse the cellular differences between benign and malignant cells. Distinct differences in the nucleic acid content of the cancer cells were revealed, and, using neural network analysis, a diagnostic sensitivity of 95% was achieved for discrimination of the cancer cell line. Building on Harris' work, Lones et al 24 applied Raman spectroscopy to analyse one benign thyroid cell line and four TC cell lines representing PTC, FTC, MTC and UTC. Alterations in either the molecular conformation or concentration of DNA/RNA, amide I and aromatic amino acids were found to be indicative of cancer.
The authors reported good discrimination of the benign cell line from MTC and UTC, and a lower discrimination between cell lines with the same cell of origin, namely benign vs DTC cell lines.
Recent studies have also investigated the feasibility of applying Raman spectroscopy to thyroid tissue samples to detect cancer.
These studies used multivariate statistical analysis of Raman spectra to achieve high diagnostic sensitivities and specificities for discrimination between healthy thyroid tissue and TC, and follicular patterned thyroid. [27] [28] [29] [30] Application of Raman spectroscopy to thyroid FNAC has not yet been reported. As a first step, the present proof-of-concept study builds on the aforementioned studies by investigating the application of Raman spectroscopy to a benign thyroid cell line and a large num- 
| Raman measurement
Raman spectra were acquired using a HORIBA Jobin Yvon XploRA ™ system (Villeneuve d'Ascq, France), which consists of an Olympus microscope BX41 supplied with a ×100 objective (MPlanN, Olympus, NA = 0.9). A 532 nm diode laser source was utilised during the study and was set at 100% power, which gave 8 mW at the objective. The confocal hole was set at 100 μm and coupled to a slit of aperture 100 μm. The system was calibrated to the 520 cm The signal-to-noise ratio was calculated by dividing the difference between the peak signal at 1665 cm −1 and the baseline intensity (smooth region after 400 cm
) by the standard deviation of the peak signal, as described by Desroches et al. 33 The mean signal-tonoise of all of the spectra included was 102 dB, which was calculated from a range of 77-159 dB.
| Data preprocessing and analysis
All spectral data analysis was conducted using R software. Preprocessing involved smoothing (Savitzy Golay k = 5, w = 15), a fifth-order polynomial baseline correction and vector normalisation. Outliers were removed using a Grubbs filter. A non-negatively constrained least squares method was used to remove interfering signals from the glass substrate. 34, 35 As described by Ibrahim et al, 34 spectra from cellular components, such as nucleic acids, proteins and lipids and the independently recorded glass spectra were used to fit the sample spectra and remove the glass contribution. The data were analysed using principal component analysis (PCA), an unsupervised method that reduces the dimensionality of the data and retains the data that are of greatest importance, known as principal components (PC). 36 Linear discriminant analysis (LDA), which maximises the separation between different classes and minimises within-class variance, was used together with PCA to develop classification model. When implemented with PCA, LDA uses the PC scores to develop the classification model. [36] [37] [38] The first PCs that explained approximately 95% of the variance within the data were used in the PC-LDA classification models.
3 | RESULTS 
| Mean spectral analysis

| Linear discriminant analysis
In order to evaluate the efficacy of Raman spectroscopy to classify the benign and TC cell lines accurately, PC-LDA classification models were developed using the principal components from PCA of the benign thyroid cell line and each of the TC cell lines. Table 2 
F I G U R E 3 Difference spectrum between (A) Nthy-ori 3-1 (benign) and 8505C (undifferentiated thyroid carcinoma); and (B) Nthy-ori 3-1 and C643 (undifferentiated thyroid carcinoma). Shading indicates regions of the spectrum that were significantly different (P < .05) positive + true negative) among all the classified spectra (true positive + true negative + false positive + false negative). 39 The first five PCs in each case were used to develop the PC-LDA classifiers. PC-LDA classification of Nthy-ori 3-1 (benign) vs PTC, FTC and MTC cell lines yielded sensitivities of ≥90%, specificities of ≥80% and accuracies of ≥89%. Lower performance was observed for the models discriminating the benign cell line from the UTC cell lines with sensitivity, specificity and diagnostic accuracy of 77%, 73% and 75%
for 8505C, and 87%, 77% and 82% for C643, respectively.
To evaluate the ability of PC-LDA to discriminate benign cells from TC subtypes, cell lines were grouped by their TC subtype. To produce an unbiased classifier, representative spectra from each cell line were selected at random and combined by TC subtype, matching the number of spectra used for the benign cell line. As XTC1 was the only cell line representing FTC, all spectra from this cell line were used, matching the number of spectra used for the benign cell line. Table 3 shows the results achieved for discriminating the benign cell line from the TC cell lines grouped by subtype. Separate two-way classification models using five PCs each were developed to discriminate the benign cells from each TC subtype. The MTC and PTC subtypes were discriminated from the benign cell line with diagnostic accuracies of at least 82%. The UTC subtype was classified at a lower accuracy of 71%. Due to similarities in their cellular biochemistry observed in this study, the well-differentiated PTC and FTC subtypes were grouped together for analysis, yielding a diagnostic accuracy of 74%. Table 4 shows the results of the two-way PC-LDA classification models used for the discrimination of the PTC and UTC cell lines, each was developed using four PCs. Each two-way classification model yielded sensitivities, specificities and diagnostic accuracies above 92% for each cell line classification. Grouped together, the PTC and UTC subtypes were discriminated with a diagnostic accuracy of 81%. Table 5 shows the results for the PC-LDA classification of MTC cell lines vs the PTC cell lines. Each classification is the result of separate two-way models using four PCs each. The models yielded specificities and diagnostic accuracies ≥93% for each cell line classification, and a diagnostic accuracy of 86% for the two-way discrimination of the MTC and PTC subtypes. with an accuracy of 99% (using four PCs), from UTC with a diagnostic accuracy of 89% (using three PCs), and from PTC with 79% accuracy (using five PCs). Table 8 demonstrates the performance of a five-way classification model developed using the benign cell spectra and spectra from all the TC subtypes. Representative spectra from each cell line were selected at random and combined into TC subtypes as previously described. The model yielded diagnostic sensitivities from 57% to 100%, specificities ≥91%, and an overall diagnostic accuracy of 78% using five PCs. Figure 5 depicts the scatter plot of the linear discriminant scores of the benign spectra and spectra from each TC subtype. The FTC spectra and the PTC spectra form two close clusters using the first two discriminant functions, which can be discriminated from the benign spectra with some overlap. The MTC spectra form a cluster along the first discriminant function, which is distinct from the benign spectra. The UTC subtype clusters adjacent to the benign spectra along the first discriminant function, although using only the first two discriminant functions to plot the scatter plot of the linear discriminant scores, the UTC and benign spectra overlap. Table 9 shows the performance of the PC-LDA model in discriminating the benign cell line from all of the TC subtypes combined into one group. As before, to produce an unbiased classifier, representative spectra from each TC subtype were selected at random and combined into one TC group, giving a total number of TC spectra that was similar to the number of benign spectra. The first five
PCs were used to develop the two-way PC-LDA model, which produced a sensitivity of 74%, specificity of 87%, and overall accuracy of 81% for discriminating benign spectra from the TC spectra. Regarding the UTC cell lines (8505C and C643), both exhibited elevated nucleic acids (~1343 cm , corresponding to increased nucleic acids, which is consistent with the findings of Harris et al. 23 The 8505C cell line also showed a higher peak intensity at 1450 cm −1 in comparison with the benign cell line, which suggests an increase in the level of proteins and lipids in the cancer cells. 40 UTC is a heterogenous disease at a molecular level, making it difficult to find commonalities between cases, which may explain the dissimilarities in the spectral profiles observed in this study between the two UTC cell lines. 42 The difference spectra of the benign vs the MTC cell lines 
| DISCUSSION
24
The MTC and FTC subtypes were discriminated with sensitivities of 100% and 94%, respectively, as observed visually in the scatter plot of the linear discriminant scores. The model also yielded a sensitivity of 79% for the UTC subtype. Multiple UTC spectra were misclassified as PTC and benign, as observed in the overlap of the clusters of these subtypes in the scatter plot of the linear discriminant scores.
The benign thyroid cell line could be discriminated from all of the TC subtypes combined into one group with a diagnostic accuracy of 81%. This is slightly higher than the 78.3% reported by Medeiros Neto et al, 31 which was achieved applying PC-LDA to Raman spectra obtained from patient thyroid tissue.
The paramount information required from the thyroid FNAC procedure is the differentiation between benign and malignant thyroid nodules. FNAC is the current favoured diagnostic method for the initial investigation of thyroid nodules, with reported sensitivity and specificity ranges of 65%-98% and 78%-100%, respectively. [43] [44] [45] [46] The results of this study show that Raman spectroscopy may also be utilised to improve the accuracy of FNAC. In our study, good sensitivities (63%-100%), specificities (65%-100%) and diagnostic accuracies (71%-99%) were achieved for the identification of TC using Raman spectroscopy on TC cell lines prepared as ThinPrep® cytology slides.
In conclusion, these data suggest a high potential for using Raman spectroscopy to improve the preoperative diagnosis of TC on FNAC samples; studies are thus warranted to directly test this application. 
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